History
-
2022
06Residual CHO gDNA Analysis Product Launched
-
2021
07Launched RCL analysis product jointly developed with
Seoul National University Hospital -
2020
12Obtained CE Mark certification
09COVID-19 RT-qLAMP PCR Diagnostic Kit Export Licensed
07R&D Partnership Agreement with Seoul National University Hospital's Advanced Cell and Gene Therapy Center
06Got permission to manufacture in vitro diagnostic medical devices
-
2019
03Obtained ISO13485 certification
-
2018
06Launched in Germany (PELOBIOTECH GmbH)
Launched in Singapore (Afirmus Biosource Pte. Ltd.)
Expanded the GMP-grade plant
04Launched in Taiwan (Tseng Hsiang Life Science Ltd.)
03Established a branch office in Singapore (Spectrum incubating, Golden Equator)
-
2017
04Launched in Japan (Primetech)
02Established a GMP-grade manufacturing plant
-
2016
12Won the prime minister’s citation
05"Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells" (patent registered, Korea)
-
2015
10“Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
-
2014
08"Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells" (2 patents registered, USA)
-
2013
08“Method for eliminating mycoplasma contamination of cells”
(Patent registered, Korea) -
2012
08Launched a diagnosis kit for the Mycoplasma qPCR
04Acknowledged company-affiliated research institute
(Korea Industrial Technology Association) -
2011
08Launched the mycoplasma-related products in the United States
-
2010
10“Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)
02Certified as a venture company (Korea Technology Finance Corporation)
-
2009
10Selected for residence in the business incubation center
of Ajou University and started the business